MC Montana, AS Evers. J Pediatr 2017; 181: 279-84. This commentary reviewed recent studies regarding anesthetic neurotoxicity. “Two recently published human studies suggest a lack of harm in otherwise-healthy children following a short duration anesthetic (approximately 1 hour)” References: Lancet 2016; 387: 239-50 & JAMA 2016; 315: 2312-20.
NR Santucci et al. JPGN 2017; 64: 186-93. This systematic review selected 31 studies (out of 916 citations) and found there is no consensus concerning diagnostic criteria for biliary dyskinesia and the data supporting the concept of biliary dyskinesia in children is weak. The uncontrolled studies were generally observational, retrospective designs with relatively small numbers.
- Biliary Dyskinesia –“Only in America”
- Rome IV -Pediatric Changes
- Quirky HIDA Study -HIDAs often Not Helpful
I Youngster et al. J Pediatr 2017; 182: 239-44. This study examined large prescription databases (more than 74 million person years) and identified wide discrepancy in antibiotic use among the six different countries. For example, among children less than 2 years of age, South Korea had the highest rate of antimicrobial use, with 3.41 prescribed courses per child-year; in contrast, the rates were 1.4 in Italy, 1.5 in Spain, 1.1 in the U.S., 1.0 in Germany, and 0.5 in Norway.
A Srivastavai et al. JPGN 2017; 64: 194-9. In this retrospective study with 262 children with liver disease-related ascites, the authors found spontaneous bacterial peritonitis (or culture-negattive neurocytic ascites) in 28.6%. Half of these patients were asymptomatic. SBP/CNNA was defined by having a polymorphonuclear leukocyte count of >250 cells/mm3. There was a 24% one-year mortality rate for those who had SBP/CNNA.
MR Narkewicz et al. JPGN 2017; 64: 210-7. Using data from the pediatric acute liver failure group, the researchers identified a high rate of autoantibodies (28%) among 986 pediatric subjects with acute liver failure. The presence of autoantibodies was not significantly associate with 21-day outcomes and steroid treatment was not associated with survival; in fact, those without a known diagnosis of autoimmune hepatitis, had a higher risk of death with steroid therapy. In the setting of acute liver failure, autoantibody positivity does not obviate the need for a complete diagnostic workup.
A Lauterio et al. Liver Transplantation 2017; 23: 184-93. Italian review of living donor safety found that major complications occurred in 12.6% (31 or 246) but there were no mortalities. 5 (2%) required reoperation.